Minerva Neurosciences (NERV) Shares Bought by Alps Advisors Inc.

Alps Advisors Inc. boosted its position in Minerva Neurosciences (NASDAQ:NERV) by 21.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,906 shares of the biopharmaceutical company’s stock after purchasing an additional 9,021 shares during the period. Alps Advisors Inc. owned approximately 0.13% of Minerva Neurosciences worth $324,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NERV. Highland Capital Management LP lifted its position in Minerva Neurosciences by 11.5% in the fourth quarter. Highland Capital Management LP now owns 2,160,544 shares of the biopharmaceutical company’s stock worth $13,072,000 after purchasing an additional 222,642 shares during the period. Sphera Funds Management LTD. lifted its position in shares of Minerva Neurosciences by 24.0% during the 4th quarter. Sphera Funds Management LTD. now owns 775,000 shares of the biopharmaceutical company’s stock valued at $4,689,000 after acquiring an additional 150,000 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Minerva Neurosciences by 3.6% during the 4th quarter. Franklin Resources Inc. now owns 1,235,000 shares of the biopharmaceutical company’s stock valued at $7,472,000 after acquiring an additional 42,700 shares during the last quarter. Ascend Capital LLC lifted its position in shares of Minerva Neurosciences by 4.8% during the 4th quarter. Ascend Capital LLC now owns 819,347 shares of the biopharmaceutical company’s stock valued at $4,957,000 after acquiring an additional 37,659 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Minerva Neurosciences by 64.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,000 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 22,400 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

A number of equities research analysts have recently commented on the company. ValuEngine upgraded Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday. BidaskClub upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. Finally, Zacks Investment Research downgraded Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Minerva Neurosciences currently has an average rating of “Hold” and a consensus price target of $12.75.

Shares of NASDAQ:NERV opened at $7.40 on Friday. Minerva Neurosciences has a one year low of $6.55 and a one year high of $6.80. The firm has a market cap of $257.68 million, a PE ratio of -6.85 and a beta of 1.43.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). sell-side analysts forecast that Minerva Neurosciences will post -1.46 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply